Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymopeptide enteric-coated tablets for immune support in idiopathic pulmonary fibrosis
ChiCTR-IPR-15005863Phase 4Recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Jan 2015
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of thymopeptide in idiopathic pulmonary fibrosis (IPF) (2 arms), sponsored by Shanghai Pulmonary Hospital. Primary endpoints: Hospitalization due to respiratory infection and acute exacerbation and Quality of life improvement. Started Jan 2015; status: recruiting.
02
Drugs
thymopeptide
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on ChiCTR-IPR-15005863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15005863.